Evidence map›Paper›PMID 25650439›Full record

ArticleStem cells translational medicine2015

An atypical human induced pluripotent stem cell line with a complex, stable, and balanced genomic rearrangement including a large de novo 1q uniparental disomy.

Clara Steichen, Jérôme Maluenda, Lucie Tosca, Eléanor Luce, Dominique Pineau, Noushin Dianat, Zara Hannoun, Gérard Tachdjian, Judith Melki, Anne Dubart-Kupperschmitt

Abstract read
In one paragraph

Article in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clara SteichenINSERM U972 and Unité Mixte de Recherche (UMR) S972, Université Paris-Sud, Paul Brousse Hospital, Villejuif, France; Département Hospitalo-universitaire Hepatinov, Paul Brousse Hospital, Villejuif, France;
Jérôme MaluendaINSERM UMR S986, Institut Fédératif de Recherche 93, Bicêtre Hospital, Kremlin-Bicêtre, France;
Lucie ToscaDepartment of Cytogenetics, Béclère Hospital, Clamart, France.
Eléanor LuceINSERM U972 and Unité Mixte de Recherche (UMR) S972, Université Paris-Sud, Paul Brousse Hospital, Villejuif, France; Département Hospitalo-universitaire Hepatinov, Paul Brousse Hospital, Villejuif, France;
Dominique PineauDepartment of Cytogenetics, Béclère Hospital, Clamart, France.
Noushin DianatINSERM U972 and Unité Mixte de Recherche (UMR) S972, Université Paris-Sud, Paul Brousse Hospital, Villejuif, France; Département Hospitalo-universitaire Hepatinov, Paul Brousse Hospital, Villejuif, France;
Zara HannounINSERM U972 and Unité Mixte de Recherche (UMR) S972, Université Paris-Sud, Paul Brousse Hospital, Villejuif, France; Département Hospitalo-universitaire Hepatinov, Paul Brousse Hospital, Villejuif, France;
Gérard TachdjianDepartment of Cytogenetics, Béclère Hospital, Clamart, France.
Judith MelkiINSERM UMR S986, Institut Fédératif de Recherche 93, Bicêtre Hospital, Kremlin-Bicêtre, France;
Anne Dubart-KupperschmittINSERM U972 and Unité Mixte de Recherche (UMR) S972, Université Paris-Sud, Paul Brousse Hospital, Villejuif, France; Département Hospitalo-universitaire Hepatinov, Paul Brousse Hospital, Villejuif, France; anne.dubart@inserm.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human induced pluripotent stem cells (hiPSCs) hold great promise for cell therapy through their use as vital tools for regenerative and personalized medicine. However, the genomic integrity of hiPSCs still raises some concern and is one of the barriers limiting their use in clinical applications. Numerous articles have reported the occurrence of aneuploidies, copy number variations, or single point mutations in hiPSCs, and nonintegrative reprogramming strategies have been developed to minimize the impact of the reprogramming process on the hiPSC genome. Here, we report the characterization of an hiPSC line generated by daily transfections of modified messenger RNAs, displaying several genomic abnormalities. Karyotype analysis showed a complex genomic rearrangement, which remained stable during long-term culture. Fluorescent in situ hybridization analyses were performed on the hiPSC line showing that this karyotype is balanced. Interestingly, single-nucleotide polymorphism analysis revealed the presence of a large 1q region of uniparental disomy (UPD), demonstrating for the first time that UPD can occur in a noncompensatory context during nonintegrative reprogramming of normal fibroblasts.

Indexed as

AneuploidyGenome, HumanCell LineCellular ReprogrammingChromosomes, Human, Pair 1FibroblastsHumansInduced Pluripotent Stem CellsUniparental DisomyAbnormal karyotypeDirected differentiationGenomic integrityInduced pluripotent stem cellsTeratoma formationUniparental disomy

Identifiers

PMID25650439
PMCPMC4339852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.